Effect of rivaroxaban on thromboprophylaxis in patients undergoing brain glioma surgery: a randomized, controlled, double-blind study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044541

Enrollment

Unknown

Registered

2021-03-23

Start date

2021-04-01

Completion date

Unknown

Last updated

2021-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain glioma

Interventions

Rivaroxaban group:Rivaroxaban P.O

placebo group:Oral placebo

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Older than 18 years old; 2. Postoperative glioma.

Exclusion criteria

Exclusion criteria: 1. Patients with clinically significant active bleeding; 2. Patients with liver disease at risk of coagulation abnormalities and clinically related bleeding; 3. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
Incidence of thrombus;	—

Secondary

Measure	Time frame
mortality;	—

Countries

China

Contacts

Public ContactWang Ziyan

The First Affiliated Hospital of Zhengzhou University

19953233457@163.com+86 19953233457

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026